MSD China's Michel Vounastos gives his initial impressions of the opportunities and challenges inherent in the Chinese healthcare market, and highlights how MSD's offerings are able to address specific gaps in the country.
You just arrived in China in February. The country managers we’ve met have all been here for some time, so I’d be interested to know how you prepared to enter such a unique and challenging market?
"There is an ageing population [in China] with an epidemiological profile that is increasingly aligned with that of the West. These are elements that favor global pharmaceutical companies in providing treatments to fit unmet needs."
